




OPEN ACCESS

Irish National Diabetic RetinaScreen Programme: report on five rounds of retinopathy screening and screen-positive referrals. (INDEAR study report no. 1)

Rajiv Pandey ,^{1,2} Margaret M Morgan,³ Colette Murphy,² Helen Kavanagh,² Robert Acheson,⁴ Mark Cahill,⁵ Patricia McGettrick,⁵ Louise O'Toole,⁴ Fatima Hamroush,⁴ Therese Mooney,⁶ Helen Byrne,⁶ Patricia Fitzpatrick,^{6,7} David J Keegan^{1,2}

► Supplemental material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bjophthalmol-2020-317508>).

For numbered affiliations see end of article.

Correspondence to

David J Keegan, Mater Misericordiae University Hospital, Mater Retinal Research Group, 60 Eccles Street, Dublin 7, Ireland; dkeegan@mater.ie

Received 20 July 2020

Revised 12 October 2020

Accepted 25 October 2020

Published Online First

17 December 2020

ABSTRACT

Objective To study the uptake of annual diabetic retinopathy screening and study the 5-year trends in the detection of screen-positive diabetic retinopathy and non-diabetes-related eye disease in a cohort of annually screened individuals.

Design Retrospective retinopathy screening attendance and retinopathy grading analysis.

Setting Community-based retinopathy screening centres for the Diabetic RetinaScreen Programme.

Participants 171 557 were identified by the screening programme to be eligible for annual diabetic retinopathy screening. 120 048 individuals over the age of 12 consented to and attended at least one screening appointment between February 2013 to December 2018.

Main Outcome Measures Detection rate per 100 000 of any retinopathy, screen-positive refractable retinopathy and nondiabetic eye disease.

Results Uptake of screening had reached 67.2% in the fifth round of screening. Detection rate of screen-positive retinopathy reduced from 13 229 to 4237 per 100 000 screened over five rounds. Detection of proliferative disease had reduced from 2898 to 713 per 100 000 screened. Non-diabetic eye disease detection and referral to treatment centres increased almost eightfold from 393 in round 1 to 3225 per 100 000 screened. The majority of individuals referred to treatment centres for ophthalmologist assessment are over the age of 50 years.

Conclusions Screening programme has seen a reduced detection rate both screen-positive retinopathy referral in Ireland over five rounds of screening. Management of nondiabetic eye diseases poses a significant challenge in improving visual outcomes of people living with diabetes in Ireland.

INTRODUCTION

Population-wide screening for diabetic retinopathy (DR) and provision of photocoagulation treatment have been shown to be effective in reducing the prevalence and incidence of blindness due to DR in a diabetic population.¹ The 2005 Liverpool Declaration by European ophthalmologists made annual retinopathy screening a priority measure to reduce the rate of blindness caused due to DR.² Today, DR is no longer the leading cause of blindness in the working-age population in England, Wales, and Iceland: nations where systematic

population-wide DR screening programmes have been implemented.^{3 4} Several features make eliminating diabetes-related blindness achievable: DR progresses in a predictable pattern, a robust internationally accepted system of disease and risk stratification exists,⁵ digital photography as a method of screening has high sensitivity and specificity,⁶ and treatments administered promptly can reduce the risk of visual impairment by at least 90%.⁷

Based on the recommendation of Health Service Executive, the healthcare regulatory body of Ireland, an annual DR screening programme was launched to offer free annual call/re-call-based diabetic retinopathy screening and treatment to people living with diabetes (PWD) aged 12 years or older. Diabetic RetinaScreen supervises annual eye screening and treatment by using a standardised retinopathy grading matrix, established urgent and routine pathways for screen-positive patients to access ophthalmological care, and provides evidence-based treatment for DR.⁸

This study aims to report on the screening activity and referral of individuals screened for DR during the first five rounds of screening. These data will also highlight changes in the frequency of presentation of DR needing urgent or routine appointments since commencement of the Irish national retinal screening programme.

METHODS

Retinopathy screening protocol

Diabetic RetinaScreen was launched in February, 2013 to reduce the risk of vision loss by screening PWD at risk of visual impairment due to DR and providing treatments before individuals develop symptoms of visual loss. A register of PWD in Ireland was created using data from government-provided medical health schemes: Medical Card Scheme, Long Term Illness Scheme, and Drugs Payment Scheme. General practitioners (GP), ophthalmologists or endocrinologists could add patients to the screening register with the patient's consent. Once registered, an invitation for screening was sent to individuals by post to confirm their identity and seek their consent to collect and analyse their data for screening. Guardians of children under the age of 16 had to provide consent and accompany their child to screening appointment.



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Pandey R, Morgan MM, Murphy C, et al. *Br J Ophthalmol* 2022;**106**:409–414.

At each screening visit, a screening technician measured individual's best corrected visual acuity with their usual distance correction and then used pinhole if the visual acuity was 6/9 or worse. Two 45° mydriatic digital photographs of the retina centred on the macula and the optic disc were used for DR grading.

The Diabetic RetinaScreen DR grading matrix is based on the English National Diabetic Eye Screening Programme (ENDESP) grading matrix.⁹ Retinal images were given a retinopathy grade of R0, R1, R2 or R3 based on the number of signs and DR lesions. Images with surrogate markers of clinically significant macular oedema (CSMO) (dot/blot haemorrhages, hard exudates, retinal thickening within one disc diameter of the fovea) were given a maculopathy grade M1, while images with no surrogate markers of CSMO were assigned a maculopathy grade of M0 (for Diabetic RetinaScreen grading matrix see online supplemental table 1). If good-quality retinal images could not be obtained, then the images were given a U, ungradable, grade, and slit lamp-based grading was conducted within 7 weeks. Individuals who were unable to complete digital screening because of immobility or other needs were screened using slit-lamp biomicroscope using the ungradable pathway, or in some instances were directly referred to a treatment centre.

Screen-negative individuals with no retinopathy (R0M0) or with only background retinopathy (R1M0) were returned to annual community-based retinal photographic screening. Screen-positive patients with background retinopathy (R1) and maculopathy (M1) were given a grade (R1M1), pre-proliferative retinopathy with or without maculopathy (R2M0/M1), and stable or active proliferative retinopathy with or without maculopathy (R3M0/M1) were referred through established pathways to treatment centres.

Urgent and routine screen-positive assessment pathways

Data regarding the number of times routine and urgent pathways were activated for individuals with screen-positive retinopathy have been reported to show the trends of screen-positive DR and nondiabetic eye diseases (NDED). The worse grade from the two eyes is used to make decisions and referrals to treatment centres. Individuals could have four possible outcomes: Urgent referral to treatment centre in 2 to 4 weeks, routine referral for assessment in 13 weeks to 18 weeks, U grade image for slit-lamp grading, or return to annual screening if patient is screen-negative. At each stage, individual's nominated GP, ophthalmologist, and/or endocrinologist was sent a letter informing them of retinopathy grade and screening outcome.

Individuals with R1M1, R2M0 and R2M1 screen-positive retinopathy and maculopathy were referred via routine pathway. Individuals with features of active or stable-treated proliferative disease graded R3 were referred via urgent access pathway to an ophthalmologist in 2 to 4 weeks. Individuals with stable-treated proliferative retinopathy were referred through the urgent pathway as there was initial concern regarding sub-optimal treatment in the diabetic population at the start of the programme.

Selected non-diabetic eye diseases (NDED) detected during annual DR screening were referred via routine referral pathway to the treatment centres (for a list of NDED referred for assessment please see online supplemental table 2). The diagnosis was confirmed by an ophthalmologist and onward referrals were made to appropriate ophthalmology clinics for follow-up and treatment. Urgent NDED related referrals were made for patients with suspected neovascular age-related macular degeneration.

Image acquisition and grading protocol

Retinopathy screening and grading of retinal screening images was done by two contracted companies Global Vision (Dublin, Ireland) and Northgate Public Services (NEC, Japan). Centralised electronic record keeping software, OptoMize (NEC, Japan) was used to store screening images and co-ordinate patient pathways through screening, slit-lamp examination and treatment. Colour retinal photographs were stored in a General Data Protection Regulation (GDPR) compliant manner in a central server from where they were viewed remotely by grading technicians, optometrists and ophthalmologists at grading centres; and, ophthalmologists at treatment centres.

Each screen-positive image went through two separate gradings by two graders to ensure grading accuracy. Every screen-positive image was reviewed by an ophthalmologist before patients were referred to treatment centres. If there was disagreement between graders then an arbitration level senior grader or ophthalmologist also graded the image before final grading. 10% of screen-negative images were automatically regraded as an internal quality assurance mechanism. Other internal quality assurance measures included continued screening technician and grading technician training involving multi-disciplinary team meetings (MDT), team training days, and internal audits, particularly regarding image quality. In addition, grading technicians were required to complete regular grading test sets from Gloucestershire Hospitals NHS Foundation Trust.

Setting

As of December 2018, Diabetic RetinaScreen provided fixed and mobile community-based screening service at 123 locations across Ireland. Each screening centre was equipped with a digital fundus camera and a 3 m Snellen chart. Images and demographic data were accessed at grading centre and treatment centres via Optomize.

Study population

Individuals with diabetes over the age of 12 years old, and with VA better than non-perception light (NPL) in the better seeing eye were eligible for screening. Individuals who attended at least one screening between February 2013 and 31 December 2018 were included in the present study. Written consents were sought at screening appointments to collect and store demographic data, fundal photographs, and treatment data for audit and quality evaluation of the programme. Individuals who did not have diabetes, unable to perceive light in both eyes, or did not consent for screening were not invited for screening. Patients already under the care of an ophthalmologist for DR management privately and patients referred to treatment centre by the Diabetic RetinaScreen programme were suspended from screening as long as their treatment continued.

Data source and ethical approval

As part of provision of screening, individuals living with diabetes are asked for a verbal consent for the use of demographic data and contact information for setting up a screening appointment. Once at the screening appointment, individuals are also asked for consent for the use of their anonymised demographics, screening images, grading data, and retinopathy treatment outcome data for the use of research, service provision studies, and screening service improvement projects. Individuals who attend retinopathy screening provide written consent for the use of their anonymised demographic, screening, grading and retinopathy treatment data to be used for the purpose of research, screening service evaluation, and quality improvement projects. Opinion from the Programme Evaluation

Unit was sought in the National Screening Service regarding the present study. This study was considered to be a screening and grading service evaluation, thus, did not require additional ethical approval.

Only individuals who have consented to the use of their retinopathy screening data to be used for research are included in this study. Only anonymised demographic data and screening outcome data were used for this study. Screening and attendance data were validated by the Programme Evaluation Unit. Data regarding screening grades and referral to treatment centres were extracted from Optimize software. Data were then anonymised using each participant's unique Diabetic RetinaScreen ID. Results of screening outcomes and attendance were then validated by the Diabetic RetinaScreen Programme Evaluation Unit.

Missing data

Rounds one and two U grade and slit-lamp assessment screening outcomes were not available for analysis. Demographic data of patients referred during the first round of screening was not available for analysis in the present study. Analysis of these variables was conducted only with available data. As there is no current integration of health records in Ireland, this study does not include analysis of referrals by type of diabetes, HbA1C concentration, body mass index, systolic or diastolic hypertension, or presence of dyslipidaemia.

Uptake rate

Uptake rate is reported for each round based on the number of patients under active management at treatment centre on 31st December of respective screening round. Patients who are discharged to routine digital screening were then annually invited to participate in DR screening, while the patients in treatment centre made up the in-care-of-ophthalmology cohort (ICO).

Uptake rate = Number of PWD attending screening in each round/(Number of PWD in the eligible cohort—Number of patients in-care-of-ophthalmology in each round of screening).

This study assessed anonymised data of individuals who attended DR and had complete retinopathy screen grading. Data are presented regarding changes in the size of the total register number, eligible cohort, demographic data of the patients eligible and those attending screening appointments throughout the study period. Retinopathy/maculopathy grades and referral outcomes were analysed and reported for patients who had attended at least one screening appointment between 1 February 2013 to 31 December 2018.

RESULTS

Attributing the roll out years of 2013 and 2014 as round one of screening, Diabetic RetinaScreen had completed five rounds of annual screening from February 2013 to 31 December 2018. By the end of round 5, there were 171 557 PWD living in Ireland eligible for annual DR screening (for eligible population gender and age breakdown please see online supplemental table 3). Over five rounds, 455 172 screening events took place, with 30 369 screen-positive DR referred to be assessed by an ophthalmologist. Screening attendance and uptake data are presented in table 1. Uptake was noted to be low in the first two rounds of screening. Highest retinopathy screening uptake was noted in the fourth round where 67.5% of the eligible population were screened.

Table 1 Total number of patients in eligible cohort, patients attending screening, and patients in-care-of-ophthalmology used in the current analysis

Screening round	Eligible population	Attended screening	Patients in-care-of-ophthalmology (ICO)	Uptake rate (%)
1	143 376	62 892	N/A	43.9%
2	149 498	79 303	7000	55.7%
3	156 855	95 040	10 500	64.9%
4	164 569	102 522	12 739	67.5%
5	171 557	105 475	14 573	67.2%

Uptake rate: Numerator=patients attending screening appointment in respective round of screening Denominator=(Population eligible in each round of screening—patients in care of ophthalmology in treatment centre).

Any retinopathy, screen-positive retinopathy, and NDED detection rate

Five rounds of retinopathy and NDED detection rate data are presented in online supplemental table 4. Rate of screen-positive retinopathy per 100 000 screened was 13 229 in round one, which had reduced to 4237 in round five. Rate of any retinopathy detection per 100 000 screened was 41 840 in round one, which reduced to 28 269 in the last round of screening. Non-diabetic eye disease (NDED) detection rate per 100 000 increased from 393 to 3225 over five rounds of screening. Detection rate of NDED during national screening increased eight-fold from round one to round five.

Routine and urgent screen-positive referrals

Over five rounds of screening completed, mean (range) 88.2% (86.7–91.6%) of individuals screened were screen-negative and returned to annual retinal photographic screening (table 2). Figure 1 represents the proportion of the screen-positive individuals referred via urgent and routine diabetic and non-diabetic eye disease pathways over five rounds of screening. Cumulative screen-positive referrals to treatment centres showed a decreasing trend from 13.6 to 7.4% in rounds one to five, respectively. As the attendance for screening had increased, screen-positive maculopathy and retinopathy referrals had declined through five rounds of screening. In the first round, 6504 (10.3%) were referred with routine screen-positive pre-proliferative retinopathy

Table 2 Screening outcomes and referral pathways activated in each round of screening

Screening round	Attended screening	Total screen-negative (%)	Routine DR referral (%)	Urgent DR referral (%)	Routine NDED referral (%)	Urgent NDED referral (%)
1	62 951	54 287 (86.7)	6504 (10.3)	1824 (2.9)	235 (0.4)	14 (0.02)
2	79 184	70 663 (89.2)	5524 (7.0)	1422 (1.8)	1350 (1.7)	89 (0.1)
3	95 040	85 256 (89.7)	4877 (5.1)	964 (1.0)	2677 (2.8)	228 (0.2)
4	102 522	93 747 (91.4)	3909 (3.8)	876 (0.8)	2571 (2.5)	292 (0.3)
5	105 475	96 596 (91.6)	3717 (3.5)	752 (0.7)	3032 (2.8)	370 (0.3)

DR, diabetic retinopathy, NDED, non-diabetic eye disease; (%), per cent of patients who attended screening in corresponding round.




Figure 1 Percentage of patients referred via routine and urgent screen-positive pathways in each round of screening. Cumulative referrals for rounds one to five of screening were: 13.6, 10.4, 9.2, 7.4 and 7.4%, respectively. DED, diabetic eye disease; NDED, nondiabetic eye disease.

with or without markers of treatable maculopathy. In the fifth round, screen-positive routine referrals had reduced to 3717 (3.5%) (table 2). Urgent PDR referrals were made for 1824 individuals (2.9%) in the first round, which had decreased to 752 (0.7%) in the fifth round (table 2).

Routine and urgent NDED referrals increased overall through five rounds of screening (table 2). Routine NDED referrals were made for 235 individuals (0.4%) to be assessed and referred for further care by an ophthalmologist. In the fifth round, routine NDED was detected in 3032 individuals (2.8%). Urgent NDED referral made for suspected neovascular AMD showed a small increase from 14 (0.02%) individuals in round one to 370 (0.35%) individuals in round five.

Slit-lamp grading and examination referrals provide a fail-safe for immobile patients and for patients with ungradable images. In round 3 to round 5 of screening, mean (range) 19.0% (16.8–23.3%) of all patients referred to treatment centres were referred after slit-lamp assessments. The majority of referrals made after slit-lamp assessment were for routine NDED (mean (range) 86.3% (84.9–88.1%)) assessment while mean (range) 2.0% (0.9–3.2%) were referred with suspected wet-AMD.

Age-based breakdown of screen-positive routine and urgent referral

72.2% (70.9–74.7%) of all patients eligible for screening were between the ages 50 and 79 years old. Figure 2A shows an age-based breakdown of all individuals referred via the urgent DED pathway with screen-positive PDR in rounds two to five. Analysis of the age of individuals with screen-positive PDR referred via urgent pathway from rounds 2 to 5 shows that the majority of individuals, mean (range) 64.3% (60.5–70%), were between the ages of 50 and 79 years old. This demographic trend is also observed in individuals who were referred for routine screen-positive DR (R1M1, R2M0, R2M1) assessment, where mean (range) 67.5% (66.6–68.2%) of the individuals referred for routine assessments were between 50 and 79 years old (figure 2B). Patients under the 30 years old made up a mean (range) 3.2% (3.1–3.4%) of the cohort screened yearly, and made up a mean (range) of 3.2% (2.3–4.5%) of the patients referred with screen-positive proliferative retinopathy in rounds 2 to 5 (figure 2A).

Retinopathy levels detected

In five rounds of screening, mean (range) 68.2% (62.4–70.6%) of all patients screened had no detectable retinopathy (table 2).





Figure 2 (A) Proportion of individuals in 10 years age brackets referred via urgent pathway with screen-positive proliferative retinopathy in rounds two to five. (B) Proportion of individuals in 10 years age brackets referred via routine diabetic eye disease pathway with screen-positive maculopathy and/or pre-proliferative retinopathy in rounds two to five.




Figure 3 Proportion of Proliferative R3/Pre-proliferative R3 retinopathy detected in each round of screening.

Screen-negative background retinopathy (R1M0) was detected in mean (range) 25.7% (22.8–28.9%) over five rounds of screening (see online supplemental table 5). The proportion of patients referred with PDR had reduced over the course of screening, from 1663 (2.6%) in round 1 to 785 (0.74%) individuals in round 5. Cumulative sight-threatening pre-proliferative (R2) and proliferative retinopathy (R3) referrals decreased from 4.5 to 1.5% from rounds 1 to 5 (figure 3).

DISCUSSION

Diabetic RetinaScreen has identified 171 557 PWD eligible for annual retinopathy screening in Ireland. Over five rounds, 445 172 screenings and gradings were completed, and 41 227 individuals were referred to treatment centres for assessment and treatment. In the screening rounds completed in 2017 and 2018, more than 100 000 individuals were screened per annum. Attendance for screening had increased from 61 951 to 105 475 (+70.3%) over five rounds. Improved patient registration, educational materials provided to patients and screening promotional activities have prompted a steady increase in attendance.

The majority of patients being referred to treatment centres by the Diabetic RetinaScreen programme were above the age of 50. This is consistent with the increasing prevalence of diagnosed diabetes in Ireland from 2.2% (95% CI 1.7 to 2.7) in 1998 to 5.2% (95% CI 5.1 to 5.3) in 2015, with the largest increase noted in the men and women in the 40–69 age group.¹⁰ This demographic trend towards screen-positive retinopathy being detected in older adults is consistent with observed association of DR and duration of diabetes.^{11–12} The UK Clinical Practice Research Datalink data analysed by Mathur *et al*¹³ also demonstrated that incidence of DR increased in parallel with increasing prevalence of diabetes.

The proportion of screen-positive retinopathy detected through national retinal screening is comparable to a previous cross-sectional prevalence study of DR conducted in Ireland before the launch of the national screening programme. In a cohort of Irish patients screened in a primary care setting¹⁴, active proliferative disease detection rate was 713 per 100 000 screened (n=1763) whereas the Diabetic RetinaScreen PDR detection rate had reduced to 713 per 100 000 (n=105 475) screened in the fifth round.

The Scottish National Diabetic Retinopathy Screening Programme (SNDRS) reported, in the first year of screening, 1.0% of the patients screened had proliferative retinopathy; this rate had declined to 0.6% in rounds 3 to 5.¹⁵ Similar declining trend was noted in the present study, detection of sight-threatening (pre-proliferative and proliferative) retinopathy had decreased from 4.5 to 1.5% annually, suggesting that the majority of previously prevalent pre-proliferative and proliferative retinopathy in the community is now being treated and monitored in diabetic retina treatment centres. The rate of screen-positive retinopathy detection per 100 000 screened had reduced from 13 229 to 4329 per 100 000 screened after five rounds of screening. The English National Diabetic Eye Screening Programme (ENDESP) has reported screen-positive retinopathy detection rate of 3121 per 100 000 screened in 2016–2017 rounds of screening.¹⁶ We feel we are on target to reduce to that level in the coming years as all the prevalent cases are identified.

Successful screening for DR relies on effective multidisciplinary cooperation. The integrated public and private model of screening and treatment may be a viable model for similarly sized nations. The introduction of a linked screening and treatment programme on an under-resourced ophthalmology network has been challenging but the benefits (through investments and process) are now being noted. Through quality assured grading in cooperation with contracted private screening providers and memorandums of understanding (MOUs) with hospitals, screening for DR in Ireland was able to be launched as a free service with screening and treatments provided by the Diabetic RetinaScreen programme. DR screening governance includes integration with the National Screening Services risk and quality standard teams. In addition, the RetinaScreen programme itself has an executive management team structure

(reporting centrally) with both a clinical advisory group and quality assurance committee to develop treatment guidelines and introduce new quality standards.

The introduction of modifications to Optimize has facilitated direct assessment of the effect of the screening programme. This integration is improving and will facilitate the acquisition of data across a patient's full screening and treatment pathway. This will aid active management of their care, identify trends in treatment response and accurately plan their return to community screening when pathology (retinopathy and/or maculopathy) is quiescent.

Our experience shows that in addition to a system to manage the initial large number of screen-positive referrals, other nations preparing to implement population-wide DR screening should have safe surveillance pathways in place to monitor individuals with low-risk mild retinopathy. As the Irish programme has evolved, new surveillance pathways have been developed to reduce number of visits for patients who have lower risk background retinopathy (R1M1 and visual acuity $\geq 6/12$ Snellen) visiting treatment centres. A surveillance programme has been established (in 2019) with the use of digital fundal photographs and OCT measurements for monitoring disease. Pilot data indicate that treatment centre referrals in this cohort can be reduced by 70–80%.

Cumulative screen-positive referrals to treatment centres in Ireland have not decreased significantly over the 5 rounds of screening this can be attributed to the steady rise in the detection rate of NDED cases (now nearly at parity with screen-positive DR referrals: 4237 DR vs 3225 NDED per 100 000 screened). Individuals referred with NDED just require one confirmatory visit and appropriate onward referral. High concordance rate between screen-positive NDED detected on screening images and ophthalmologists assessments in treatment centres highlight the opportunity presented by including selected ocular conditions where screening for those pathologies alone would not have been cost-effective. Through robust screening and grading protocols many nondiabetic ocular conditions are being detected earlier in Ireland. This, on one hand, reflects a significant achievement of the screening programme in identifying and promptly sending patients to treatment centres with sight-threatening NDED. However, the chronic shortage of capacity in the Irish Eye Service to manage and treat the wide range of ocular conditions has led to frustration for patients and their ophthalmologists. Initiatives such as the Primary Eye Care review¹⁷ and the National Eye Care Plan¹⁸ are helping by developing primary care ophthalmology centres to provide treatments for nondiabetic eye diseases in the community.

Currently, the large number of screen-positive NDED detected during screening represents a significant challenge to optimising visual outcomes for PWD in Ireland. In nations where ophthalmic care for common ocular conditions is not available DR screening will present an opportunity to provide individuals with sight-threatening nondiabetic ocular conditions access to care. These pathologies should be treated contemporaneously to prevent referrals of these individuals to treatment centres for reasons other than DR.

National data reveal that patients with no health insurance, living in deprived economic areas are at higher risk of having undiagnosed diabetes¹⁹ and have higher prevalence of diabetes.²⁰ The Cycle of Care Programme²¹ has formalised diabetes care for patients in Ireland, as part of the programme GPs shall register all new diabetic patients with the annual screening programme and collate anonymised systemic data on a central database. This has already improved the number of individuals registered for screening by Diabetic RetinaScreen.

Strengths of the study are (a) the inclusion of data from a national retinopathy screening programme, (b) accurate retinopathy grading data, and (c) five rounds of national retinopathy screening outcome information. The national RetinaScreen cohort eligible for screening represents the biggest database of PWD in the country. This study did not include analysis of referral data based on the duration of disease, type of diabetes, medications used to control glycaemia, or medications used to control hypertension (as this data is not integrated into patients' health record yet).

Now that more than 171 000 PWD have been identified to be eligible for screening, we expect that we will continue to increase access to screening for all people living with diabetes in Ireland. We have had a steady start to our national diabetic retinopathy screening and treatment programme. Attendance at screening has increased and retinopathy detection rates were at similar rates seen in other annual retinopathy screening programmes. Significant numbers of patients have received treatment for DR at treatment centres and many more are actively being monitored. Further studies of visual outcomes of Diabetic RetinaScreen patients will show the impact screening has had on rates of visual impairment in the screened cohort.

Author affiliations

¹Diabetic RetinaScreen, National Screening Service, Health Service Executive, Dublin, Ireland

²Mater Retinal Research Group, Mater Misericordiae University Hospital, Dublin, Ireland

³Department of Ophthalmology, Letterkenny University Hospital, Letterkenny, Ireland

⁴Diabetic Retinal Screening Service, Northgate Information Solutions Ltd, Hemel Hempstead, UK

⁵Global Vision, Centric Health Ltd, Dublin, Ireland

⁶Programme Evaluation Unit, National Screening Service, Dublin, Ireland

⁷Department of Public Health, University College Dublin, Dublin, Ireland

Acknowledgements We would like to thank the individuals attending screening who allowed their data to be used for this research. We would like to thank the many staff members working at Diabetic RetinaScreen, National Screening Service, Programme Evaluation Unit, Global Vision, Northgate Public Services, University College Dublin, and Mater Misericordiae University Hospital Ophthalmology Department for providing access to data and computing power to accomplish this research.

Contributors RP analysed the data, contributed to the discussion, wrote and edited the manuscript.; DK conceptualized and administrated the project, and contributed to the discussion and edited the manuscript; CM and HK supervised the project, contributed to the acquisition of data and reviewed the manuscript; PF, TM, HB contributed to the acquisition of data, and edited and reviewed the manuscript; MM, PM, FH, RA, MC, LOT, contributed to the writing of methodology, and edited and reviewed the manuscript.

Funding This work was supported through grants provided by the National Screening Service, Dublin, Ireland and the Mater Vision Institute, Dublin, Ireland. There were no award grant numbers associated with funding.

Competing interests MC is a beneficial owner of Global Vision (Dublin, Ireland).

Ethics approval Only anonymised demographic data and screening outcome data were used for this study. Screening and attendance data was validated by the Programme Evaluation Unit.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which

permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Rajiv Pandey <http://orcid.org/0000-0003-1061-2150>

REFERENCES

- Kristinsson JK, Hauksdottir H, Stefansson E, *et al*. Active prevention in diabetic eye disease: a 4-year follow-up. *Acta Ophthalmol Scand* 1997;75:249–54.
- Harding S, ed. *Screening for diabetic retinopathy in Europe 15 years after the St. Vincent declaration: the liverpool declaration 2005 [Report of conference]. 17th–18th November 2005*. Liverpool: Screening for Diabetic Retinopathy in Europe, 2006. Available www.drscreening2005.org.uk (accessed Jan 2020)
- Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. *BMJ Open* 2014;4:e004015.
- Stefansson E, Bek T, Porta M, *et al*. Screening and prevention of diabetic blindness. *Acta Ophthalmol Scand* 2000;78:374–85.
- Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified airle house classification: ETDRS report number 10. *Ophthalmology* 1991 May; 98: 786–806.
- Scanlon PH, Malhotra R, Greenwood RH, *et al*. Comparison of two reference standards in validating two field mydriatic digital photography as a method of screening for diabetic retinopathy. *Br J Ophthalmol* 2003;87:1258–63.
- Ferris FL. How effective are treatments for diabetic retinopathy? *JAMA* 1993;269:1290–1.
- National Screening Service Quality Assurance Committee for Diabetic Retinopathy Screening. *Standards for quality assurance in diabetic retinopathy screening*. 1st edn, rev. 5. Dublin: National Screening Service, 2019. Available https://www.diabeticretinascreen.ie/_fileupload/Documents/DR-PUB-Q-1%20Rev%204%20Standards%20for%20Quality%20Assurance%20in%20Diabetic%20Retinopathy%20Screening.pdf (accessed Jan 2020)
- Scanlon PH. The english national screening programme for diabetic retinopathy 2003–2016. *Acta Diabetologica* 2017;54:515–25.
- Younis N, Broadbent DM, Vora JP, *et al*. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the liverpool diabetic eye study: a cohort study. *Lancet* 2003;361:195–200.
- Thomas RL, Dunstan FD, Luzio SD, *et al*. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. *Br J Ophthalmol* 2015;99:64–8.
- Tracey ML, Gilmartin M, O'Neill K, *et al*. Epidemiology of diabetes and complications among adults in the republic of Ireland 1998–2015: a systematic review and meta-analysis. *BMC Public Health* 2015;16:1–3.
- Mathur R, Bhaskaran K, Edwards E, *et al*. Population trends in the 10-year incidence and prevalence of diabetic retinopathy in the UK: a cohort study in the clinical practice research datalink 2004–2014. *BMJ Open* 2017;7:e014444.
- Mc Hugh S, Buckley C, Murphy K, *et al*. Quality-assured screening for diabetic retinopathy delivered in primary care in Ireland: an observational study. *Br J Gen Pract* 2013;63:e134–40.
- Looker HC, Nyangoma SO, Cromie DT, *et al*. Rates of referable eye disease in the Scottish national diabetic retinopathy screening programme. *Br J Ophthalmol* 2014;98:790–5.
- Public Health England. Diabetic eye screening: 2016 to 2017 data. [Internet] Sheffield, England. June 2018. Available <https://www.gov.uk/government/publications/diabetic-eye-screening-2016-to-2017-data> (accessed 2020 Apr)
- Primary care eye services review group report [Internet]. *Health Service Executive*. April 2017. Available <http://www.hse.ie/eng/services/publications/Primary/Eye-Services-Review-Group-Report.pdf> (accessed Jan 2020)
- Irish College of Ophthalmologists. *National clinical programme for ophthalmology: model of eye care*. Dublin: Health Service Executive, May 2017. Available <https://www.hse.ie/eng/services/publications/primary/eye-services-review-group-report.pdf> (accessed Jan 2020)
- Leahy S, O' Halloran AM, O' Leary N, *et al*. Prevalence and correlates of diagnosed and undiagnosed type 2 diabetes mellitus and pre-diabetes in older adults: findings from the irish longitudinal study on ageing (TILDA). *Diabetes Res Clin Pract* 2015;110:241–9.
- O'Connor JM, Millar SR, Buckley CM, *et al*. The prevalence and determinants of undiagnosed and diagnosed type 2 diabetes in middle-aged irish adults. *PLoS ONE* 2013;8:e080504–10.
- Irish College of General Practitioners. *A practical guide to integrated type 2 diabetes care*. Dublin: Irish College of General Practitioners, 2016. Available <https://www.icgp.ie/speck/properties/asset/asset.cfm?type=LibraryAsset&id=C3F97550%20D0DF5%20DEB2C%20D1F51D41D68A13B89&property=asset&revision=tip&disposition=inline&app=icgp&filename=ICGP%5FGuide%5Fto%5FIntegrated%5FT2D%5F2%5F2%5F2016%20Epdf> (accessed Jan 2020)